Navigation Links
Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference
Date:6/3/2010

MOUNTAIN VIEW, Calif., June 3 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that company President and CEO Thomas B. King will present during the Jefferies 2010 Global Life Sciences Conference.  The Alexza presentation will be on Thursday, June 10, 2010 at 3:00 pm ET.  The presentation will be webcast from the Grand Hyatt Hotel in New York, NY.

To access the presentation via the Web, please go to the Investor Relations tab at www.alexza.com or at http://www.wsw.com/webcast/jeff46/alxa/.  A replay of the webcast will be made available approximately 24 hours after the live presentation and the replay will be archived for 14 days.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.  

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, submitted a New Drug Application  in December 2009, and has a Prescription Drug User Fee Act (PDUFA) goal date of October 11, 2010.  In February 2010, Alexza established a partnership with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 in the U.S. and Canada.    

Alexza has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine) and has completed two Phase 2 studies with AZ-104 (Staccato loxapine, low-dose). Both product candidates are being developed for the acute treatment of migraine headache.  

AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial.  Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, and AZ-007 (Staccato zaleplon) for the treatment of insomnia.  More information, including this and past press releases from Alexza, is available online at www.alexza.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties.  Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs.  The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements.  These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission.  Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
2. Alexza Pharmaceuticals to Present at The Ninth Annual JMP Securities Research Conference
3. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
4. Alexza Pharmaceuticals Files Shelf Registration Statement
5. Alexza to Announce 2010 First Quarter Financial Results on Monday, May 10, 2010
6. Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
7. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
8. Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
9. Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010
10. Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA
11. Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... DIEGO , Feb. 22, 2017 ... first-in-class therapies for both rare and common malignancies, ... Series B financing. The company intends to use ... cirmtuzumab and TK216, and to advance preclinical development ... Cirmtuzumab is a first-in-class anti-ROR1 monoclonal ...
(Date:2/22/2017)... Florida , February 22, 2017 ... Industries is becoming more and more prevalent today ... Cannabinoids & THC Extracts as well as other ... to medicinal cannabis and marijuana therapies and their ... new relationships and assets designed to bring the ...
(Date:2/22/2017)... CHENNAI and HAMBURG, Germany , February ... leader in precision oncology headquartered in Hamburg, Germany ... premier academic research institution, announced today a collaboration to support the ... precision cancer research. ... IITM and Indivumed signed an agreement with an initial three-year term. ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus ... the latest innovation in the delivery of Platelet Rich Plasma (PRP). PRP systems ... pain management, to accelerate tissue synthesis and provide a faster and more efficient ...
(Date:2/22/2017)... ... February 22, 2017 , ... Super-Sod will attend the Athens Home Show ... Georgia. , A shift from Super-Sod’s simple Athens Home Show booth of 2016, this ... grass seed plant manager Chris Roquemore constructed furniture from recycled pallet wood at the ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... threats. Yet with so many different solutions on the market, it is easy ... choices, Texas Premier Locksmith offers a complimentary security consultation. , Home ...
(Date:2/21/2017)... ... 2017 , ... Author Michèle Wolff has a passion for using food ... know all about it for optimal health. Wanting to share her knowledge to the ... and Wellness Solutions ” (published by Balboa Press AU). , This book inspires ...
(Date:2/21/2017)... ... February 21, 2017 , ... As recently as 2015, rhinoplasty was one ... Society of Plastic Surgeons. Some patients want to make a change in the appearance ... improve their breathing ability. The team at usrhinoplasty.org is expanding its article ...
Breaking Medicine News(10 mins):